Prepare for the American Board of Pediatric Dentistry Oral Boards. Utilize flashcards and multiple-choice questions with hints and explanations to ace your exam!

Multiple Choice

In aggressive periodontitis treatment, Metronidazole is given at 250 mg TID with Amoxicillin at what per-dose range?

When treating aggressive periodontitis with systemic antibiotics, the goal is to broaden coverage against the diverse subgingival flora, including anaerobes and facultative bacteria, while keeping the regimen tolerable. Metronidazole at 250 mg taken three times daily targets anaerobic pathogens effectively. Pairing it with amoxicillin expands coverage to include organisms like Actinomyces and other Gram-positive facultative bacteria, creating a synergistic effect that improves overall antimicrobial reach. The amoxicillin dose per administration is typically in the 250–375 mg range when used with metronidazole. Administering within this range three times daily maintains adequate antibiotic levels in the crevicular fluid and systemic circulation, enhancing efficacy without pushing the daily dose into higher-risk territory for adverse effects or resistance. Subtherapeutic dosing, such as 125–250 mg or lower, would not provide sufficient systemic exposure in combination therapy. On the other hand, doses like 500 mg per dose would exceed the intended range and may increase side effects without additional benefit in this specific synergistic regimen.

When treating aggressive periodontitis with systemic antibiotics, the goal is to broaden coverage against the diverse subgingival flora, including anaerobes and facultative bacteria, while keeping the regimen tolerable. Metronidazole at 250 mg taken three times daily targets anaerobic pathogens effectively. Pairing it with amoxicillin expands coverage to include organisms like Actinomyces and other Gram-positive facultative bacteria, creating a synergistic effect that improves overall antimicrobial reach.

The amoxicillin dose per administration is typically in the 250–375 mg range when used with metronidazole. Administering within this range three times daily maintains adequate antibiotic levels in the crevicular fluid and systemic circulation, enhancing efficacy without pushing the daily dose into higher-risk territory for adverse effects or resistance.

Subtherapeutic dosing, such as 125–250 mg or lower, would not provide sufficient systemic exposure in combination therapy. On the other hand, doses like 500 mg per dose would exceed the intended range and may increase side effects without additional benefit in this specific synergistic regimen.